Phase II radioimmunotherapy trial with131I-CC49 in colorectal cancer
| Autor: | V. A. Bhadkamkar, Hua‐Zhong ‐Z Zhang, Joan E. Cunningham, Donald A. Podoloff, L. P. Kasi, Daniel J. Macey, James L. Murray, Paula Trahan Rieger, Michael G. Rosenblum, Jeffrey Schlom |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Cancer Research
medicine.medical_specialty Response to therapy business.industry Colorectal cancer medicine.drug_class medicine.medical_treatment Urology medicine.disease Monoclonal antibody Oncology Refractory Radioimmunotherapy Toxicity Medicine Radiolabeled CC49 In patient business Nuclear medicine |
| Zdroj: | Cancer. 73:1057-1066 |
| ISSN: | 1097-0142 0008-543X |
| Popis: | Background. Radiolabeled CC49, a second generation high affinity monoclonal antibody (MoAb) reactive with tumor-associated glycoprotein 72 (TAG72) has undergone previous Phase I testing in patients with colon cancer. Based on this report, the authors treated 15 refractory metastatic colon cancer patients with 131 I-CC49 to determine its overall toxicity and the response to therapy of patients treated with it, Methods. Patients received 75 mCi/m 2 131 I-CC49 (20 mg MoAb) intravenously for a period of 30-60 minutes. Whole body retention was derived from the measured dose-rate of I-131 monitored daily at 1 m using an ion chamber. Two whole-body and static-gamma camera images were taken of patients on days 4 and 7 after the infusion |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text